The News section features the latest regulatory and clinical news in oncology, as well as expert insights on the latest cancer treatments. Read more at OncLive.
Cancer-treatment-induced neurotoxicity--focus on newer treatments Cancer-treatment-induced neurotoxicity-focus on newer treatments. Nature reviews Clinical oncology. 2016; 13:92-105. doi: 10.1038/ nrclinonc.2015.152.Stone JB and DeAngelis LM (2016) Cancer-treatment-induced neurotoxicity[mdash]focus ...
more than double the 25% of trials in Phase I. The total of oncology trials far exceeds the next therapy area of central nervous system treatments, which has 4,043 trials expected to complete this year. These figures roughly continue the trend from clinical trials projected to ...
Limited research has outlined the nature of the original new drugs in China to understand the dynamic response of the market. Methods The objective of this article was to map the clinical development of approved new oncology drugs in China from 2015 to 2021 and differed from previous studies by...
trial of vorasidenib, and highlight the questionable choice of control intervention and end points, ethical concerns, as well as the uncertain efficacy observed, and argue that the approval might be premature given the high cost of this drug and lack of clear benefit over standard treatments. ...
New Treatment Options for Relapsed/Recurrent DLBCL: Impact on Sequencing Therapeutic Choices June 26th 2024 Five medical provide insights around breakthrough treatment strategies in relapsed/recurrent DLBCL. Evolving Treatments of Metastatic CRC: Insights from ASCO 2024 June 25th 2024 John Marshall, MD; ...
A new treatment regimen for patients with metastatic colon cancer appears to offer clinical benefit even when used after multiple other treatments have failed, say research physicians at Georgetown Lombardi Comprehensive Cancer Center, a part of Georgeto
Effective October 31, 2022, the new Sarah Cannon Research Institute joint venture is a fully integrated oncology research organization aimed at expanding clinical research, accelerating drug development and increasing availability and access to clinical trials for community oncology providers and patients, ...
Compass Oncology offers access to more cancer clinical trials than anywhere in the Portland and Vancouver area.
56.65% in 2024 in the workflow segment, and it is anticipated to expand at the highest CAGR from 2025 to 2030. The segment's dominance is due to the rising focus of industry players on NGS technology for oncology treatments, and NGS sequencing is an important step in the complete wor...